{"entity":{"id":"bi-1206","kind":"drug","name":"BI-1206","aka":["BI1206"],"tldr":"BI-1206 is an experimental monoclonal antibody from BioInvent International, in phase 2 trials for non-small-cell lung cancer, uveal melanoma and non-Hodgkin lymphoma and other cancers.","summary":"BI-1206 (BI1206) is a monoclonal antibody from BioInvent International, with Merck & Co. as partner. A high-affinity monoclonal antibody that selectively binds FcγRIIB (CD32B), the only inhibitory member of the FcγR family, intended to address a mechanism of resistance to PD-1 inhibition; tested with pembrolizumab and with rituximab. Its furthest stage is phase 2, for non-small-cell lung cancer, uveal melanoma, non-Hodgkin lymphoma and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1/2a NCT04219254 (with pembrolizumab, MSD collaborator) recruiting (registry, checked 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"BioInvent International: bioinvent.com","url":"https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1206pembrolizumab"},{"label":"BioInvent International: bioinvent.com","url":"https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1206pembrolizumab"},{"label":"ClinicalTrials.gov: trials of BI-1206","url":"https://clinicaltrials.gov/search?intr=BI-1206"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["fcgr2b"],"drugs":[],"companies":["bioinvent-international","merck"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04219254"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BI-1206","modality":"Monoclonal antibody","mechanism":"A high-affinity monoclonal antibody that selectively binds FcγRIIB (CD32B), the only inhibitory member of the FcγR family, intended to address a mechanism of resistance to PD-1 inhibition; tested with pembrolizumab and with rituximab.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bi-1206/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"fcgr2b","kind":"target","name":"FCGR2B","route":"/targets/fcgr2b/"}],"company":[{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"trial":[{"id":"nct04219254","kind":"trial","name":"A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","route":"/trials/nct04219254/"}]}}